Wishing you a very Happy Birthday | Dr. Dimitri P. Mikhailidis

 

Dr. Dimitri

 

Dr. Dimitri P. Mikhailidis serves as the Editor-in-Chief of the Journal “Current Vascular Pharmacology”

Dimitri P. Mikhailidis
(33295 citations)
Academic Head, Department of Clinical Biochemistry
Royal Free Hospital Campus
University College London Medical School
University College London (UCL)
Pond Street
London, NW3 2QG
UK

Biography

Press Release | Bentham Science journals improve impact factor ratings in 2019

 

The latest edition of Journal Citation Reports® 2019 has been published recently, and according to the report, Bentham Science Publishers (BSP) journals have significantly improved their Impact Factors. Current Neuropharmacology is leading the list again with the highest impact factor (IF: 4.568) among all the journals. In total, 40 BSP journals have received Impact Factor ratings this year. The latest results in the JCR 2019 reflect the high quality of research published by Bentham Science.

Journal Citation Reports (JCR) is an annual publication by Clarivate Analytics. JCR has been integrated with the Web of Science and is accessible from the Web of Science-Core Collections. Its purpose is to offer a systematic means to critically evaluate the world’s leading journals, with quantifiable, statistical information based on citation data.

Bentham Science publishes over 100 print & online scholarly subscription journals and books. Learn more about Bentham Science here: http://www.benthamscience.com

 

Read full press release to find out more at: https://www.eurekalert.org/pub_releases/2019-06/bsp-bsl062019.php

Wishing you a very Happy Birthday | Dr. Dimitri P. Mikhailidis

 

Dr Dimitri  P Mikhailidis- bentham.jpg

 

Dr. Dimitri P. Mikhailidis

Editor in Chief: Current Vascular Pharmacology

Academic Head, Department of Clinical Biochemistry
Royal Free Hospital Campus
University College London Medical School
University College London (UCL)
Pond Street
London, NW3 2QG
UK

New Issues of various Bentham Science Journals

 

1. Cardiovascular & Hematological Agents in Medicinal Chemistry, Vol: 16, Issue:1

https://bit.ly/2AWUnwp

2. Letters in Organic Chemistry, Vol: 15, Issue: 10

https://bit.ly/2QCmhCY

3. Current Vascular Pharmacology, Vol: 16, Issue: 6

https://bit.ly/2AVbmiI

4. Current Pharmaceutical Design, Vol: 24, Issue: 17

https://bit.ly/2PSKAzs

5. Recent Patents on Inflammation & Allergy Drug Discovery, Vol: 12, Issue: 2

https://bit.ly/2QrcEqY

6. Current Organic Chemistry, Vol: 22, Issue: 15

https://bit.ly/2SXAnAH

7. Current Pharmaceutical Design, Vol: 24, Issue: 18

https://bit.ly/2PK2qF3

8. Recent Patents on Biotechnology, Vol: 12, Issue: 3

https://bit.ly/2z29KlC

9. Mini-Reviews in Medicinal Chemistry, Vol: 18, Issue: 16

https://bit.ly/2qCXROI

 

 

Issues.jpg

AIMS & SCOPE – Current Vascular Pharmacology

Aims & Scope:

Current Vascular Pharmacology publishes clinical and research-based reviews, original research articles, letters, debates, drug clinical trial studies and guest edited issues to update all those concerned with the treatment of vascular disease, bridging the gap between clinical practice and ongoing research.

Vascular disease is the commonest cause of death in Westernized countries and its incidence is on the increase in developing countries. It follows that considerable research is directed at establishing effective treatment for acute vascular events. Long-term treatment has also received considerable attention (e.g. for symptomatic relief). Furthermore, effective prevention, whether primary or secondary, is backed by the findings of several landmark trials. Vascular disease is a complex field with primary care physicians and nurse practitioners as well as several specialties involved. The latter include cardiology, vascular and cardio thoracic surgery, general medicine, radiology, clinical pharmacology and neurology (stroke units).

 

cvp-flyer.jpg

 

For more details, please visit: https://benthamscience.com/journals/current-vascular-pharmacology/aims-scope/#top

MOST ACCESSED ARTICLE – Antithrombotic Therapy After TAVR

Journal Name: Current Vascular Pharmacology

Author(s): Tobias Geisler*, Michal Droppa, Karin Muller, Oliver Borst.

Graphical Abstract:

 

Abstract:

Transvascular Aortic Valve Replacement (TAVR) has emerged as a treatment option in patients with severe aortic stenosis who are inoperable and has recently been evaluated in patients with intermediate surgical risk. The number of procedures is increasing worldwide in parallel with the demographic changes in industrial countries. The risk for cerebral embolism is of main concern and represents a major determinant for prognosis and quality of live after TAVR. The empiric antithrombotic therapy consists of Dual Antiplatelet Therapy (DAPT); However the risk-benefit of this approach is lacking evidence from randomized, placebo-controlled trials regarding choice and duration of antithrombotic treatment. Although anticoagulation is generally not recommended in patients with aortic bioprosthesis without atrial fibrillation, there is current uncertainty whether combination of antiplatelet and anticoagulant therapy or anticoagulation alone might represent a more favorable antithrombotic regimen compared to the current empiric standard of DAPT. In addition, so far undetected atrial fibrillation is highly prevalent in the elderly population undergoing TAVR. In particular, the favorable safety profile of Non-Vitamin K Oral Anticoagulants (NOAC) offers an attractive option. A number of trials are currently underway to investigate the benefit of NOAC in patients with and without atrial fibrillation undergoing TAVR. The present article reviews the available evidence concerning stroke risk in TAVR patients and the current and future role of antithrombotic therapy during and after the procedure.

For more details, please visit: http://www.eurekaselect.com/159150

OPEN ACCESS ARTICLE – Pathophysiology of Diabetic Dyslipidaemia

Journal Name: Current Vascular Pharmacology

Author(s): Theodosios Filippatos, Vasilios Tsimihodimos, Eleni Pappa, Moses Elisaf*.

 

 

 

Graphical Abstract:

Abstract:

Background: Patients with diabetes usually exhibit diabetic dyslipidaemia.

Aim: The aim of the review is to present the quantitative and qualitative alterations of lipids and lipoproteins and the associated mechanisms in patients with diabetic dyslipidaemia.

Results: The main quantitative changes observed in patients with diabetic dyslipidaemia are increased triglycerides and decreased high-density lipoprotein (HDL) cholesterol levels. Qualitative abnormalities mainly include increased small dense low-density lipoprotein (LDL) particles (despite similar serum LDL cholesterol levels as non-diabetic subjects) and alterations in the apolipoprotein content of HDL particles. Alterations in the activities of enzymes involved in lipoprotein metabolism, such as cholesteryl ester transfer protein, and the lipoprotein content of lipid particles, along with their glycation and oxidation, play a role in the pathogenesis of diabetic dyslipidaemia.

Conclusion: Diabetic dyslipidaemia is associated with quantitative and qualitative alterations of lipids and lipoproteins, which are associated with increased cardiovascular risk.

 

For more details, please visit: http://www.eurekaselect.com/149655

THEMATIC ISSUE – Insulin Therapy, Insulin resistance and vascular dysfunction

THEMATIC ISSUE OF THE JOURNAL: CURRENT VASCULAR PHARMACOLOGY

“Insulin Therapy, Insulin resistance and vascular dysfunction”

Guest Editor(s): Luis Sobrevia

 

cvp-Dr Professor Luis Sobrevia.jpg

New Issue :: Current Vascular Pharmacology (Volume: 16, Issue: 5)

 

Current Vascular Pharmacology publishes clinical and research-based reviews, original research articles, letters, debates, drug clinical trial studies and guest edited issues to update all those concerned with the treatment of vascular disease, bridging the gap between clinical practice and ongoing research.

Vascular disease is the commonest cause of death in Westernized countries and its incidence is on the increase in developing countries. It follows that considerable research is directed at establishing effective treatment for acute vascular events. Long-term treatment has also received considerable attention (e.g. for symptomatic relief). Furthermore, effective prevention, whether primary or secondary, is backed by the findings of several landmark trials. Vascular disease is a complex field with primary care physicians and nurse practitioners as well as several specialties involved. The latter include cardiology, vascular and cardio thoracic surgery, general medicine, radiology, clinical pharmacology and neurology (stroke units).

 

cvp

 

Articles from the journal Current Vascular Pharmacology Volume 16 Issue 5:

 

For details on the articles, please visit this link ::  https://bit.ly/2JJgKqk

 

EDITOR’S CHOICE – Association between Apolipoproteins AI and B and Ultrasound Indicators of Carotid Atherosclerosis

Journal: Current Vascular Pharmacology

Author(s): Zeljko Zivanovic*, Ivana Divjak, Mirjana Jovicevic, Tamara Rabi-Zikic, Biljana Radovanovic,Svetlana Ruzicka-Kaloci, Djordje Popovic, Edita Stokic, Ksenija Gebauer-Bukurov, Katarina Zivanovic-Vujcic,Petar Slankamenac

Graphical Abstract:

 

Abstract:

Background: Apolipoproteins A-I and B (apoA-I and apoB) may be better indicators of the risk of cardiovascular and cerebrovascular diseases than conventional risk factors (RFs). The onset of ischemic stroke (IS) may be preceded by the development of atherosclerotic changes in carotid arteries, which can be detected by ultrasound. Only a certain % of patients with IS have an (underlying) carotid etiology.

Objective: The aim of our study was to determine the association between ultrasound indicators of carotid atherosclerosis and the presence of apolipoproteins and other biomarkers in patients with IS.

Methods: The study included 120 patients with clinically first, non-cardioembolic ischemic stroke in the carotid circulation. For all patients the following data were recorded: risk factors (hypertension, diabetes, hyperlipoproteinemia, smoking, obesity, metabolic syndrome, (MetS) hyperhomocysteinemia and inflammation), and levels of blood pressure, glucose, glycosylated hemoglobin, lipids, apoA-I and apoB apolipoproteins, body mass index, homocysteine, and C-reactive protein (CRP). Carotid duplex ultrasound was used to measure carotid intima media thickness (cIMT) and determine the presence of an unstable (hypoechogenic) plaque.

Results: The most significant associations were found between cIMT and older age (β=0.230; p=0.006), lower concentrations of apoA-I (β=-0.244; p=0.008) and a higher apoB/apoA-I ratio (β=0.247; p=0.007). The presence of a hypoechogenic plaque was most significantly associated with increased concentrations of apoB (OR=2.29; 95% CI=4.9-173.5; p<0.0001), the presence of MetS (OR=9.2; 95% CI=2.9-29.2; p<0.0001) and elevated CRP (OR=2.7; 95% CI=1.1-6.9; p = 0.046).

Conclusion: Among RFs and their biomarkers, apoA-I, apoB and the apoB/apoA-I ratio showed strong association with ultrasound indicators of carotid atherosclerosis in IS patients.

Read more here: http://www.eurekaselect.com/156319/article

 

%d bloggers like this: